The current status of gene therapy in bladder cancer
INTRODUCTION: Gene therapy aims to alter the biological properties of cells through the therapeutic delivery of nucleotides to treat a disease. Although originally developed to treat genetic disorders, the majority of gene therapy development today is for the treatment of cancer, including bladder cancer.
AREAS COVERED: Following a brief history and a discussion of the mechanisms of gene therapy, we will focus on the current and future gene therapy strategies for bladder cancer. We will review the most consequential clinical trials published in the field.
EXPERT OPINION: Recent transformative breakthroughs in bladder cancer research have deeply characterized the major epigenetic and genetic alterations of bladder cancer and have radically transformed our view of tumor biology and generated new hypotheses for therapy. These advances provided the opportunity to begin to optimize strategies for effective gene therapy for bladder cancer. Clinical trials have shown promising results, especially in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), where effective second-line therapy remains an unmet need for patients facing cystectomy. Efforts are underway to develop effective combination strategies targeting resistance mechanisms to gene therapy for NMIBC.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:23 |
|---|---|
| Enthalten in: |
Expert review of anticancer therapy - 23(2023), 5 vom: 14. Mai, Seite 531-543 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Tholomier, Côme [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adjuvants, Immunologic |
|---|
| Anmerkungen: |
Date Completed 28.04.2023 Date Revised 03.05.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/14737140.2023.2203385 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355602075 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355602075 | ||
| 003 | DE-627 | ||
| 005 | 20231226064706.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/14737140.2023.2203385 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1185.xml |
| 035 | |a (DE-627)NLM355602075 | ||
| 035 | |a (NLM)37055873 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Tholomier, Côme |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The current status of gene therapy in bladder cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.04.2023 | ||
| 500 | |a Date Revised 03.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a INTRODUCTION: Gene therapy aims to alter the biological properties of cells through the therapeutic delivery of nucleotides to treat a disease. Although originally developed to treat genetic disorders, the majority of gene therapy development today is for the treatment of cancer, including bladder cancer | ||
| 520 | |a AREAS COVERED: Following a brief history and a discussion of the mechanisms of gene therapy, we will focus on the current and future gene therapy strategies for bladder cancer. We will review the most consequential clinical trials published in the field | ||
| 520 | |a EXPERT OPINION: Recent transformative breakthroughs in bladder cancer research have deeply characterized the major epigenetic and genetic alterations of bladder cancer and have radically transformed our view of tumor biology and generated new hypotheses for therapy. These advances provided the opportunity to begin to optimize strategies for effective gene therapy for bladder cancer. Clinical trials have shown promising results, especially in BCG-unresponsive non-muscle-invasive bladder cancer (NMIBC), where effective second-line therapy remains an unmet need for patients facing cystectomy. Efforts are underway to develop effective combination strategies targeting resistance mechanisms to gene therapy for NMIBC | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Bladder cancer | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a gene therapy | |
| 650 | 4 | |a genetic vectors | |
| 650 | 4 | |a molecular genetics | |
| 650 | 4 | |a viral vectors | |
| 650 | 7 | |a BCG Vaccine |2 NLM | |
| 650 | 7 | |a Adjuvants, Immunologic |2 NLM | |
| 700 | 1 | |a Martini, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Mokkapati, Sharada |e verfasserin |4 aut | |
| 700 | 1 | |a Dinney, Colin P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Expert review of anticancer therapy |d 2001 |g 23(2023), 5 vom: 14. Mai, Seite 531-543 |w (DE-627)NLM11982020X |x 1744-8328 |7 nnns |
| 773 | 1 | 8 | |g volume:23 |g year:2023 |g number:5 |g day:14 |g month:05 |g pages:531-543 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/14737140.2023.2203385 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 23 |j 2023 |e 5 |b 14 |c 05 |h 531-543 | ||